https://www.selleckchem.com/pr....oducts/way-316606.ht
a at rest in hospitalized non-hypoxemic cancer patients. Larger studies are needed to confirm these findings.(Clinicaltrials.govNCT02932332) IMPLICATIONS FOR PRACTICE This double-blind, 4x4 crossover trial examined the effect of oxygen or air delivered at high or low flow rate on dyspnea in hospitalized non-hypoxemic cancer patients. High flow oxygen and high flow air were significantly better at reducing dyspnea than low flow oxygen/air, supporting a role for palliation beyond oxygenation.Mesoporous bioactive glass nanoparticles (MB